Mark Andrew White - 04 Apr 2023 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Chief Medical Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for Mark Andrew White
Issuer symbol: RCKT
Transactions as of: 04 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 12 Apr 2023, 19:00:22 UTC
Next filing: 21 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock, par value $0.01	Award	$0	+76,662		$0.000000	76,662	04 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Stock Option (Right to Buy)	Award	$0	+57,739		$0.000000	57,739	04 Apr 2023	Common Stock	57,739	$17.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
F2	This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.